These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 29961057)

  • 21. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
    J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind, placebo-controlled phase 2 study of the augmentation of a nicotinic acetylcholine receptor partial agonist in depression: is there a relationship to leptin levels?
    Fava M; Ramey T; Pickering E; Kinrys G; Boyer S; Altstiel L
    J Clin Psychopharmacol; 2015 Feb; 35(1):51-6. PubMed ID: 25422883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
    Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Items of the Montgomery-Åsberg Depression Rating Scale Associated With Response to Paroxetine Treatment in Patients With Major Depressive Disorder.
    Tomita T; Sato Y; Nakagami T; Tsuchimine S; Kaneda A; Kaneko S; Nakamura K; Yasui-Furukori N
    Clin Neuropharmacol; 2016; 39(3):135-9. PubMed ID: 27171569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder.
    Sato Y; Yasui-Furukori N; Nakagami T; Saito M; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):416-8. PubMed ID: 19166896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder.
    Katila H; Mezhebovsky I; Mulroy A; Berggren L; Eriksson H; Earley W; Datto C
    Am J Geriatr Psychiatry; 2013 Aug; 21(8):769-84. PubMed ID: 23567397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Observational study to evaluate the clinical benefit of lamotrigine add-on therapy in bipolar patients in a naturalistic treatment setting.
    Woo YS; Bahk WM; Pae CU; Jeong JH; Koo BH; Jon DI; Lee JG; Kim MD
    Asia Pac Psychiatry; 2014 Sep; 6(3):334-41. PubMed ID: 24038834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial.
    Berk M; Copolov DL; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Bush AI
    Biol Psychiatry; 2008 Sep; 64(6):468-75. PubMed ID: 18534556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. QEEG Theta Cordance in the Prediction of Treatment Outcome to Prefrontal Repetitive Transcranial Magnetic Stimulation or Venlafaxine ER in Patients With Major Depressive Disorder.
    Bares M; Brunovsky M; Novak T; Kopecek M; Stopkova P; Sos P; Höschl C
    Clin EEG Neurosci; 2015 Apr; 46(2):73-80. PubMed ID: 24711613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
    Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
    J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder.
    Bauer M; Thase ME; Liu S; Earley W; Eriksson H
    J Psychopharmacol; 2015 May; 29(5):565-74. PubMed ID: 25257148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.
    Han C; Wang SM; Kwak KP; Won WY; Lee H; Chang CM; Tang TC; Pae CU
    J Psychiatr Res; 2015; 66-67():84-94. PubMed ID: 26013203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Venlafaxine for treatment-resistant unipolar depression.
    Nierenberg AA; Feighner JP; Rudolph R; Cole JO; Sullivan J
    J Clin Psychopharmacol; 1994 Dec; 14(6):419-23. PubMed ID: 7884023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lamotrigine treatment of adolescents with unipolar and bipolar depression: a retrospective chart review.
    Shon SH; Joo Y; Lee JS; Kim HW
    J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):285-7. PubMed ID: 24813210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Social anxiety symptoms across diagnoses among outpatients attending a tertiary care mood and anxiety disorders service.
    Graystone HJ; Garner MJ; Baldwin DS
    J Affect Disord; 2009 Apr; 114(1-3):305-9. PubMed ID: 18656267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
    Tohen M; Vieta E; Calabrese J; Ketter TA; Sachs G; Bowden C; Mitchell PB; Centorrino F; Risser R; Baker RW; Evans AR; Beymer K; Dube S; Tollefson GD; Breier A
    Arch Gen Psychiatry; 2003 Nov; 60(11):1079-88. PubMed ID: 14609883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament.
    Manning JS; Haykal RF; Connor PD; Cunningham PD; Jackson WC; Long S
    J Affect Disord; 2005 Feb; 84(2-3):259-66. PubMed ID: 15708424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study.
    Bares M; Brunovsky M; Kopecek M; Stopkova P; Novak T; Kozeny J; Höschl C
    J Psychiatr Res; 2007; 41(3-4):319-25. PubMed ID: 16889798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
    Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
    Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.